ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.488
-0.73%
Brent Oil
83.76
0.00%
Bitcoin
66,782.21
-0.24%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. ChromaDex Corporation (CDXC)

  7. ChromaDex Corporation (CDXC) Noticias

CDXC

ChromaDex (CDXC)

ChromaDex Corporation
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CDXC
FechaHoraFuenteTítuloSímboloCompañía
08/05/202415:04Business WireChromaDex Corporation Reports First Quarter 2024 Financial ResultsNASDAQ:CDXCChromaDex Corporation
08/05/202415:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CDXCChromaDex Corporation
08/05/202415:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CDXCChromaDex Corporation
30/04/202407:32Business WireChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy SupplementNASDAQ:CDXCChromaDex Corporation
25/04/202407:34Business WireChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®NASDAQ:CDXCChromaDex Corporation
24/04/202407:34Business WireChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024NASDAQ:CDXCChromaDex Corporation
23/04/202407:32Business WireChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers MarketNASDAQ:CDXCChromaDex Corporation
26/03/202407:32Business WireChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency ProgramNASDAQ:CDXCChromaDex Corporation
06/03/202415:04Business WireChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 ResultsNASDAQ:CDXCChromaDex Corporation
06/03/202415:01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CDXCChromaDex Corporation
23/02/202420:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CDXCChromaDex Corporation
21/02/202407:32Business WireChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024NASDAQ:CDXCChromaDex Corporation
05/02/202407:32Business WireChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024NASDAQ:CDXCChromaDex Corporation
26/01/202415:08Business WireChromaDex to Present at the Lytham Partners 2024 Investor Select ConferenceNASDAQ:CDXCChromaDex Corporation
20/12/202308:04Business WireChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®NASDAQ:CDXCChromaDex Corporation
12/12/202309:30PR Newswire (US)Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+NASDAQ:CDXCChromaDex Corporation
30/11/202307:34Business WireA Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)NASDAQ:CDXCChromaDex Corporation
15/11/202307:32Business WireNewly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) PatientsNASDAQ:CDXCChromaDex Corporation
09/11/202307:32Business WireChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023NASDAQ:CDXCChromaDex Corporation
08/11/202315:02Business WireChromaDex Corporation Reports Third Quarter 2023 Financial ResultsNASDAQ:CDXCChromaDex Corporation
01/11/202307:34Business WireChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers NationwideNASDAQ:CDXCChromaDex Corporation
31/10/202307:34Business WireChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023NASDAQ:CDXCChromaDex Corporation
26/10/202307:32Business WireChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ LineNASDAQ:CDXCChromaDex Corporation
02/10/202307:32Business WireA Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis PatientsNASDAQ:CDXCChromaDex Corporation
07/09/202305:20Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CDXCChromaDex Corporation
24/08/202307:32Business WirePreclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMNNASDAQ:CDXCChromaDex Corporation
09/08/202315:02Business WireChromaDex Corporation Reports Second Quarter 2023 Financial ResultsNASDAQ:CDXCChromaDex Corporation
08/08/202307:34Business WireChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and WellnessNASDAQ:CDXCChromaDex Corporation
07/08/202307:32Business WireChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow SeriesNASDAQ:CDXCChromaDex Corporation
02/08/202307:02Business WireChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023NASDAQ:CDXCChromaDex Corporation
 Showing the most relevant articles for your search:NASDAQ:CDXC

Su Consulta Reciente

LSE
58UZ
Newday 26 S
USOTC
SHLAF
Schindler Holding Ag Her... (PK)
NASDAQ
FTKURX
E Commerce Opportunity P...
EU
ETANH
Republic of France 0.75%...
LSE
88YC
Municplty 26
TSXV
TNZ
Tenaz Energy
EU
N592Z
N592Z
USOTC
TBTC
Table Trac (QX)
NYSE
TVL
Lin TV
NASDAQ
FEGIKX
Market Strength Allocati...
DOWI
DJUSGR
DJ US Growth
AMEX
XTC.X
AQSE
IQO
Inteliqo
COIN
STOCNETH
LSE
QU39
Morg.st.b.v 27
BIT
S29116
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados